Moderna a catalyst driven idea at Morgan Stanley
By Sam Boughedda Morgan Stanley analysts labeled Moderna (NASDAQ:MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock. The...
Buy
or
GSK plc DRC News & Analysis
-
-
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding...
-
Microdermabrasion Devices Market Report (2022 to 2030) - Novartis AG, Pfizer Inc., Sanofi AG, Merck & Co. Inc. and GSK Plc
Pune, Dec. 14, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global microdermabrasion devices market is expected to clock US$ 1,042.4...
-
Wave Life Sciences Soars on GSK Deal
Shares of clinical-stage genetic medicine provider Wave Life Sciences (NASDAQ:WVE) are soaring higher today after the company announced a key collaboration with GSK (NYSE:GSK) with a focus...
-
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
Wave Life Sciences Ltd (NASDAQ: WVE) and GSK plc (NYSE: GSK) have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing...
-
Wave, GSK enter strategic collaboration
Shares of Wave Life Sciences Ltd. jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline to develop...
-
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave's PRISM™ oligonucleotide...
-
Rs 10 lakh penalty imposed on GlaxoSmithKline for misleading ad, parliamentary panel told
These are among the five cases where the CCPA has imposed penalties on entities for issuing misleading advertisements with false claims and adopting unfair means to misguide consumers. Apart...
-
-
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a...
-
China trade slump, Apple woes, central bank meetings - what's moving markets
By Geoffrey Smith Investing.com -- China announced more measures loosening COVID-19 health measures after new data showed its trade slowed sharply in November. Apple's iPhone production is...
-
GSK, Sanofi shares rise after U.S. judge dismisses Zantac cancer link lawsuits
By Scott Kanowsky Investing.com -- Shares in GSK plc (LON:GSK) and Sanofi SA (EPA:SASY) soared on Wednesday after the drugmakers saw tens of thousands of lawsuits involving the heartburn...
-
GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac
(Reuters) – Drugmakers GSK Plc, Pfizer Inc, Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac...
-
GSK gets regulatory nod to launch shingles vaccine in India
Piyali Mukherjee, vice president and head of global medical affairs, vaccines, at GSK said the virus is there in 90% of adults and whenever the immunities hit, the virus is reactivated and...
-
We might need an annual booster shot: Global medical lead, GSK
Even as Covid-19 numbers continue to recede across the globe, experts still believe that different options will be needed to deal with the viral infection even if it heads towards becoming a...
-
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial...
-
'Uncertain times ahead': GlaxoSmithKline stock falls 4% as UBS moves to Sell
By Senad Karaahmetovic Shares of GlaxoSmithKline (NYSE:GSK) are trading more than 4.5% lower in pre-market U.S. trading today after UBS analysts downgraded to Sell from Neutral as the pharma...
-
Haleon hits 3-month high after raising full-year profit outlook
By Geoffrey Smith Investing.com -- Shares in Haleon (NYSE:HLN), formerly the consumer health division of GlaxoSmithKline (NYSE:GSK), hit their highest in three months on Thursday after the...
-
GSK Slumps After Blood Cancer Drug Blenrep Falls Short in Clinical Trial
By Geoffrey Smith Investing.com -- GlaxoSmithKline (NYSE:GSK) stock fell over 4% on Monday after the U.K.-based pharma company said its experimental bone-marrow cancer drug DREAMM-3...
-
GlaxoSmithKline ADR earnings, Revenue miss in Q3
Investing.com - GlaxoSmithKline ADR reported on Wednesday third quarter {{erl-22459||earnings that missed analysts' forecasts and revenue that fell short of expectations. GlaxoSmithKline...
-
GlaxoSmithKline Posts Q3 Results, Lifts Outlook
GlaxoSmithKline (GSK) reported Q3 EPS of GBP0.47, versus the analyst estimate of GBP0.93. Revenue for the quarter came in at GBP7.8 billion versus the consensus estimate of GBP8.24...
-
CVS Health, AMD, Yum Brands Rise Premarket; Estée Lauder, Airbnb Fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, November 2nd. Please refresh for updates. CVS Health (NYSE:CVS) stock rose 0.9% after the healthcare company...
-
GSK Raises Annual Outlook After Shingles Vaccine Helps Boost Q3 Results
By Scott Kanowsky Investing.com -- Shares in GlaxoSmithKline (LON:GSK) moved higher on Wednesday after the drugmaker lifted its full-year earnings and sales outlook following...
-
European Stock Futures Higher; Fed Decision Looms Large
By Peter Nurse Investing.com - European stock markets are expected to open higher Wednesday, continuing the recent positive trend ahead of the conclusion of the crucial Federal Reserve...
-
Dow Futures Trade Steady as Investors Brace for Fed Hike
By Oliver Gray Investing.com - U.S. stock futures were trading in a tight range during Tuesday’s evening deals, after major benchmark averages retreated during the regular session as market...
-
U.S. CPI, Saudi Pushback, Earnings Season Ramp-Up - What's Moving Markets
By Geoffrey Smith Investing.com -- The U.S. will release inflation data for September, which are expected to show another chunky rise in core prices. Jobless claims, which snapped a...
-
GSK: Trials for Respiratory Virus Vaccine "Positive"
By Scott Kanowsky Investing.com -- GlaxoSmithKline plc (LON:GSK) has announced that its vaccine for respiratory syncytial virus for adults aged 60 and above showed overall efficacy of...
-
Burberry Rises After Tapping Daniel Lee to Replace Tisci as Creative Head
By Geoffrey Smith Investing.com -- Shares in Burberry (LON:BRBY) rose on the news that highly-rated Daniel Lee will succeed Riccardo Tisci as chief creative officer, who confirmed his...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
